Background: To Investigate whether the g.4760C>T polymorphism in the promoter region of the catalase gene (CAT) is a risk factor for primary angle closure glaucoma (PACG) in the Saudi population.Methods: 138 unrelated PACG patients and 403 unrelated control subjects from Saudi Arabia were genotyped for a single nucleotide polymorphism (SNP; rs1001179; g.4760C>T) utilizing Taq-Man® assay. The association between different genotypes and various clinical indices important for PACG was also investigated.Results: The distribution of different genotypes was comparable between both study groups. The genotype " C/C" was predominant among cafses; 94 (68.1%) and controls; 289 (71.7%). Heterozygous genotype " C/T" , was present in 41 (29.7%) of cases and 103 (25.6%) of controls, where the homozygous variant genotype was present in only 3 (2.2%) of cases and 11 (2.7%) of the controls. The distribution of variant allele was similar in both study groups (p= 0.568). Interestingly, there was a trend of association between the type of the variant (homozygous variant, heterozygous and wildtype genotype) and one important parameter for PACG, which is visual acuity. The visual acuity increase was; 0.62 (±0.74), 0.88 (±0.88) and 1.27 (±0.95) in patients carrying the " C/C" , " C/T" and " T/T" genotypes respectively, which was statistically significant in both ANOVA and pairwise individual T tests (p = 0.022, 0.031 and 0.039) when compared to controls.Conclusions: This variant is possibly associated with visual acuity in PACG patients and thus had the potential to be used as a parameter for assessing PACG severity. © 2013 Abu-Amero et al.; licensee BioMed Central Ltd.
CITATION STYLE
Abu-Amero, K. K., Azad, T. A., Mousa, A., Osman, E. A., Sultan, T., & Al-Obeidan, S. A. (2013). A catalase promoter variant rs1001179 is associated with visual acuity but not with primary angle closure glaucoma in Saudi patients. BMC Medical Genetics, 14(1). https://doi.org/10.1186/1471-2350-14-84
Mendeley helps you to discover research relevant for your work.